Free Trial

JPMorgan Chase & Co. Sells 6,618 Shares of Relx Plc (NYSE:RELX)

Relx logo with Computer and Technology background
Remove Ads

JPMorgan Chase & Co. trimmed its position in Relx Plc (NYSE:RELX - Free Report) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 819,863 shares of the technology company's stock after selling 6,618 shares during the quarter. JPMorgan Chase & Co.'s holdings in Relx were worth $37,238,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RELX. LGT Group Foundation bought a new stake in shares of Relx during the 4th quarter valued at approximately $257,000. Paradigm Asset Management Co. LLC boosted its position in Relx by 17.1% in the fourth quarter. Paradigm Asset Management Co. LLC now owns 81,600 shares of the technology company's stock valued at $3,706,000 after buying an additional 11,900 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Relx by 120.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 12,066 shares of the technology company's stock worth $548,000 after buying an additional 6,588 shares during the last quarter. Merit Financial Group LLC acquired a new position in shares of Relx during the fourth quarter worth $301,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Relx by 19.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 143,483 shares of the technology company's stock valued at $6,517,000 after acquiring an additional 23,183 shares during the last quarter. 15.02% of the stock is currently owned by institutional investors and hedge funds.

Relx Trading Up 0.1 %

RELX traded up $0.04 during trading on Friday, reaching $49.06. 1,831,813 shares of the stock traded hands, compared to its average volume of 725,864. The company has a quick ratio of 0.47, a current ratio of 0.52 and a debt-to-equity ratio of 1.46. The stock's 50-day moving average is $49.29 and its 200 day moving average is $47.87. Relx Plc has a 12 month low of $40.25 and a 12 month high of $51.99. The stock has a market capitalization of $90.79 billion, a PE ratio of 26.37, a P/E/G ratio of 2.73 and a beta of 0.84.

Remove Ads

Relx Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be given a dividend of $0.5586 per share. This is a positive change from Relx's previous semi-annual dividend of $0.23. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 1.6%. Relx's dividend payout ratio is presently 59.68%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on RELX shares. The Goldman Sachs Group assumed coverage on Relx in a research report on Wednesday, March 26th. They set a "buy" rating on the stock. Redburn Atlantic began coverage on shares of Relx in a report on Wednesday, January 8th. They set a "buy" rating on the stock. StockNews.com cut Relx from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Finally, Barclays upgraded Relx from an "equal weight" rating to an "overweight" rating in a report on Friday, March 14th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy".

Read Our Latest Stock Report on Relx

Relx Company Profile

(Free Report)

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.

See Also

Institutional Ownership by Quarter for Relx (NYSE:RELX)

Should You Invest $1,000 in Relx Right Now?

Before you consider Relx, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relx wasn't on the list.

While Relx currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

5 Stocks to BUY Now as Tariff Uncertainty Fades
WWE Stock Could Explode Next Week — Now’s the Time to Buy Into TKO
These 3 Dividend Stocks Might Be the Safest Bet Right Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads